四川医学2011，Vol.32Issue(1)：4-6,3.
羧甲司坦联合低剂量沙美特罗/氟替卡松治疗稳定期中重度慢性阻塞性肺疾病多中心临床研究
Effect of carbocisteine and salmeterol and low dose fluticasone propionate on acute exacerbation of chronic obstructive pulmonary disease
摘要
Abstract
Objective To observe the benefits and safety of combination of carbocisteine and sahneterol and low dose fluticasone(50/100μg) on reducing the yearly exacerbation rate in patients with COPD. Methods 80 patients with COPD were recruited from outpatient departments in the central hospital of Mianyang, the people's hospital of Guizhou province and the third people's hospital of Chengdu. They were treated in randomized, open, parallel-group, positive-controlled study with either combination of Carbocisteine and low dose sahneterol/fluticasone (50/100μg)( treatment group) or sahneterol/fluticasone (50/500μg) (control group) for one year. The exacerbation rate over 1 year,St George's respiratory questionnaire (SGRQ) scores,and side effects were recorded. Results Of 80 patients, the exacerbations per patient-year of treatment group is 1.2 (95％ CI,1.14～1.30), while the control group is 1.1 (95％ CI, 1.03 ～1.14) ). There is no significant difference between the two groups. St George's respiratory questionnaire (SGRQ) scores decreased by 5.54 and 5.59 in treatment group and control group,respectively. There is no significant difference between treatment group and control group. Adverse events of both groups were not significant different, however, events of pneumonia is higher in control group. Conclusion Combination of carbocisteine and sahneterol and low dose fiuticasone (50/100μg) may be beneficial on treating stable COPD. The probability of having pneumonia was greater for patients who were treated by sahneterol and high dose fluticasone (50/500μg).关键词
慢性阻塞性肺疾病/治疗/羧甲司坦/沙美特罗/氟替卡松分类
医药卫生引用本文复制引用
徐治波,唐永江,邱婷,刘维佳,陈斌,廖蕾..羧甲司坦联合低剂量沙美特罗/氟替卡松治疗稳定期中重度慢性阻塞性肺疾病多中心临床研究[J].四川医学,2011,32(1):4-6,3.基金项目
中华医学会临床医学慢性呼吸道疾病科研专项资金项目(编号:08020560134) （编号:08020560134）
四川省卫生厅研究项目(编号:030360) （编号:030360）
